Results 51 to 60 of about 14,479 (218)

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

Advanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong, Yuhang Xie, Zhijie Weng, Yongzhi Wu, Longjiang Li, Bo Li   +5 more
wiley   +1 more source

Improvement of Radioimmunotherapy Using Pretargeting [PDF]

, 2013
During the past two decades, considerable research has been devoted to radionuclide therapy using radiolabeled monoclonal antibodies and receptor binding agents.
Caroline Bodet-Milin, Caroline Rousseau, Eric Frampas, Françoise Kraeber-Bodéré, Jacques Barbet, Jean-Francois Chatal   +5 more
core   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

Cascade‐Responsive MXene@Cu‐MOF Heterostructure Integrates Antioxidant Activity, Infection Control, and Vascularization for Tracheal Repair

Advanced Science, EarlyView.
A cascade‐responsive MXene@Cu‐MOF/GelMA hydrogel is engineered as a “skeleton–backpack” platform for extensive tracheal repair. The MXene framework scavenges postoperative ROS and converts NIR light into mild hyperthermia, while the Cu‐MOF component provides pH/NIR‐responsive Cu2+ dosing for infection control, angiogenesis, and chondrogenesis.
Liang Guo, Yingran Shen, Jiaoyu Yi, Juanjuan Li, Ziming Wang, Erji Gao, Siqiang Zheng, Zhe‐Sheng Chen, Bo Tao   +8 more
wiley   +1 more source

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

Advanced Science, EarlyView.
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu, Mengtao Sun, Lusheng Li, Jieqiong Wang, Shibiao Wan   +4 more
wiley   +1 more source

Good practices for 89Zr radiopharmaceutical production and quality control

EJNMMI Radiopharmacy and Chemistry
Background During the previous two decades, PET imaging of biopharmaceuticals radiolabeled with zirconium-89 has become a consistent tool in preclinical and clinical drug development and patient selection, primarily due to its advantageous physical ...
Thomas Erik Wuensche, Serge Lyashchenko, Guus A. M. S. van Dongen, Danielle Vugts   +3 more
doaj   +1 more source

Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin’s lymphoma

Exploration of Targeted Anti-tumor Therapy
Radioimmunotherapy (RIT) is a therapy that combines a radioactive nucleotide with a monoclonal antibody (mAb). RIT enhances the therapeutic effect of mAb and reduces toxicity compared with conventional treatment.
Hiroki Goto, Yoshioki Shiraishi, Seiji Okada   +2 more
doaj   +1 more source

Triple negative breast cancer: nanosolutions for a big challenge [PDF]

, 2015
Triple negative breast cancer (TNBC) is a particular immunopathological subtype of breast cancer that lacks expression of estrogen and progesterone receptors (ER/PR) and amplification of the human epidermal growth factor receptor 2 (HER2) gene ...
Adams, Aebi, Ahn, Ali, Almuhaideb, Arpino, Awada, Ayala-Orozco, Bar, Baselga, Baselga, Baselga, Bauer, Bawarski, Bertos, Bianco, Boyle, Brigger, Brown, Burke, Burstein, Cardoso, Carey, Chen, Chen, Cho, Crisp, Crown, Dai, Davis, DeNardo, Dent, Dogan, Duncan, Engebraaten, Fauzee, Feng, Ferrari, Ferraro, Finlay, Franchina, Ghosh, Goldhirsch, Gonzalez-Angulo, Gref, Grobmyer, Gu, Hammond, Herranz, Hirsch, Hong, Huang, Hun, Hussein, Iida, Inoue, Jain, Jain, Jin, Johnstone, Joshi, Julien, Kadioglu, Kang, Kaur, Kircher, Ko, Krag, Kucuk, Kutty, Kutty, Lainé, Lamprecht, Lay, LeBeau, Lee, Lehmann, Li, Liu, Ljubimova, Ljubimova, Lund, Lyshchik, Ma, Ma, Maeda, Matsumura, Matsumura, Meier, Meng, Mikhail, Mittapalli, Montagna, Mura, O'Toole, Oakman, Ossovskaya, Owens, Palma, Park, Passarella, Passarella, Penault-Llorca, Raha, Raoof, Reubi, Rodrigues, Rodrigues, Rousseau, Sahoo, Schmadeka, Sharma, Sharma, Shi, Shi, Siegel, Svenson, Tacar, Tan, Taurin, Tekedereli, Thomas, Tinoco, Tobio, Torchilin, Tran, Turner, van Scheltinga, van Scheltinga, Wang, Wang, Yu, Yu, Zhu   +133 more
core   +1 more source

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

Advanced Science, EarlyView.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård, Tatiana Bobrova, Amalie Leinebø, Thibault Leray, Shayamita Ghosh, Lorena García‐Hevia, Chiara Puccinelli, Lorenzo Riccio, Jacopo Sorani, Davide Bonifazi, Julien Caumartin, Emmanuel Donnadieu, Florence Gazeau, Roland Hischier, Else Marit Inderberg, Mónica L. Fanarraga, Maria Loustau, Bernd Nowack, Sébastien Wälchli, Cécilia Ménard‐Moyon   +19 more
wiley   +1 more source

Anti-PSMA 124I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principle

Journal of Experimental & Clinical Cancer Research, 2019
Background Prostate cancer (PCa) is the second leading cause of cancer-related death in the Western population. The use in oncology of positron emission tomography/computed tomography (PET/CT) with emerging radiopharmaceuticals promises accurate staging ...
B. Frigerio, S. Morlino, E. Luison, E. Seregni, A. Lorenzoni, A. Satta, R. Valdagni, A. Bogni, C. Chiesa, M. Mira, S. Canevari, A. Alessi, M. Figini   +12 more
doaj   +1 more source